Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
about
Extremophilic 50S Ribosomal RNA-Binding Protein L35Ae as a Basis for Engineering of an Alternative Protein ScaffoldCanadian hereditary angioedema guideline.Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency.Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group.Pediatric hereditary angioedema due to C1-inhibitor deficiency.Management of upper airway edema caused by hereditary angioedema.Ecallantide for the treatment of hereditary angiodema in adults.Directed evolution of three-finger toxin to produce serine protease inhibitors.Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiencyNew treatments addressing the pathophysiology of hereditary angioedemaWAO Guideline for the Management of Hereditary AngioedemaOestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment.Treatment of hereditary angioedema with plasma-derived C1 inhibitorPlasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeabilityClinical Immunology Review Series: An approach to the patient with angio-oedema.Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.Treatment of Hereditary Angioedema: items that need to be addressed in practice parameter.Therapeutic approaches in hereditary angioedema.New topics in bradykinin research.Update on treatment of hereditary angioedema.Optimizing hereditary angioedema management through tailored treatment approaches.Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.In vitro-engineered non-antibody protein therapeutics.Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.New drugs approved in 2009Treatment of type I and II hereditary angioedema with Rhucin, a recombinant human C1 inhibitor.Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2).Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors.Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients.Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgeryNew promise and hope for treating hereditary angioedema
P2860
Q28547051-7AF484EA-A06F-40EC-A71C-4FB29FB1DA45Q30596332-B233F4D7-7F2D-4600-94F2-7274975BC718Q33560367-5E2A98E1-98AD-4590-B660-99011F193CC6Q34029593-A69D4E23-B969-4F8F-A379-2A5BC750008EQ34060664-035C4281-FACE-4BB7-A917-5C55D6CB23FCQ34060670-0CFE0E90-9B82-4BD0-BD75-8FF98670679BQ35046998-6B562656-B891-4B00-95F7-9D4B2EBCEB69Q35059556-98D0D0C0-1D1B-4068-8E2C-51C8E00F788FQ35096965-281F413F-F3DD-4DFB-A43E-8ECDC188E779Q36642688-5A8DBC51-369A-4E95-9AA0-FD00B3B86549Q36834816-669E768F-86E0-4A24-9CFF-4A3F49FD1D6CQ37028371-2E89F214-900E-4256-8F9B-7DC822B94DDCQ37052806-5C808910-23BD-40FA-B49D-D173062580AEQ37161400-66F6A064-7B7F-4720-8CE9-6681B25CA925Q37394385-3A519203-7034-447C-B01B-FDDFFE97B01CQ37729036-9519ED34-5AC8-41BC-A962-3DC29648E1F9Q37760289-E62FFF1D-CF89-45BE-BB61-EC11ADCA0EFBQ37833531-1A30C60E-DE49-4AC5-896F-FB17DDB03CFBQ37920922-BD31FDB2-CD28-4B2B-A609-92B2DFE3427FQ38091703-B8CAB19C-A2A5-47FB-BEBB-B0FAA7029559Q38615008-A57870D8-C731-484A-BF5E-AA85072C526CQ38790498-C8A8EF4C-8239-40C1-A994-68FA901BF9D7Q39167522-BA214A12-40CD-4E21-B627-D2BCA6E61532Q39254938-FF0456F3-1D1E-40F4-A9F2-D779AAD7421CQ39863212-048D5F84-1B57-49F4-8147-1511A5789131Q40031791-9B107DE1-B7D0-45A4-86A5-7EFF6A6D5720Q41982669-AADEBF97-FA8B-4E36-87BA-7CD462A21063Q42869354-B6ED5B34-7282-4E1B-B09E-8397BA6FB6ECQ45329636-47A87FD2-8755-442B-9CE2-51E55460FB10Q46166466-88572F07-AED3-485D-889D-E506FB9342EFQ47796115-D4192F7F-14BF-45A3-8998-EAB0AC73C0A2Q56031831-4B3C29D9-0D3A-4B0F-BD08-9FA0FB0D6153Q58615572-0E7AD9F8-4F09-4D0D-9785-7197C4705D3B
P2860
Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@ast
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@en
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@nl
type
label
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@ast
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@en
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@nl
prefLabel
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@ast
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@en
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@nl
P2093
P1476
Critical role of kallikrein in ...... a novel kallikrein inhibitor.
@en
P2093
Anthony H Williams
Arthur Vegh
Lynda Schneider
Tess Schmalbach
William Lumry
P304
P356
10.1016/J.JACI.2007.04.028
P407
P577
2007-06-07T00:00:00Z